Axon Therapies is a technology company.
Axon Therapies has raised $32.0M across 1 funding round.
Axon Therapies has raised $32.0M in total across 1 funding round.
Axon Therapies is a clinical-stage medical technology company developing the Satera™ Ablation System for Splanchnic Ablation for Volume Management (SAVM), a minimally invasive, implant-free catheter-based procedure to treat heart failure by targeting overactivity in the sympathetic nervous system.[1][2][3][6] It primarily serves cardiology patients with heart failure, including those with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF), addressing a root cause of disease progression—volume overload and sympathetic nerve hyperactivity—that current therapies often fail to resolve effectively.[1][3][4][6] The company has raised $42.8M total, including a $32M oversubscribed Series A in September 2025, fueling pivotal trials amid strong early clinical data from studies like REBALANCE-HF showing safety, tolerability, and responder improvements in functional capacity and biomarkers.[3][7]
Axon Therapies was founded in 2014 by MedTech incubator Coridea in Santa Clara, California, emerging from research on splanchnic nerve ablation to manage volume in heart failure patients.[1][3][5] Co-founder Zoar Engelman, PhD, transitioned from Chief Scientific Officer to CEO in September 2025 alongside the Series A raise, bringing deep expertise in the therapy's science.[3] Early milestones include $10.8M in prior funding (last in 2019 from Deerfield Management), 21 patents focused on heart failure devices, and pivotal feasibility studies like REBALANCE-HF, which validated the procedure's safety and efficacy signals in HFpEF patients.[1][2][3][7]
Axon rides the wave of device-based neuromodulation in cardiology, targeting the HFpEF epidemic—where 50% of heart failure cases occur but therapies are scarce—amid rising global incidence driving hospitalizations and deaths.[3][4][6] Timing aligns with maturing catheter tech and post-COVID heart failure surges, bolstered by peer-reviewed evidence from REBALANCE-HF establishing SAVM as a feasible frontline option.[7] Market tailwinds include demand for minimally invasive alternatives to drugs or implants, influencing medtech by validating nerve ablation for volume management and potentially expanding to HFrEF, reshaping treatment paradigms.[1][2][7]
Axon is primed for pivotal trials with fresh $32M capital, positioning SAVM for FDA clearance and commercialization as a breakthrough for underserved HFpEF patients.[3] Neuromodulation trends and expanding HFrEF data could broaden adoption, while partnerships with clinical centers accelerate evidence-building. Expect influence growth through regulatory wins and scale, transforming heart failure care from reactive to causal—echoing its mission to rebalance a deadly disease.
Axon Therapies has raised $32.0M in total across 1 funding round.
Axon Therapies's investors include Earlybird Venture Capital, EQT Life Sciences, Seroba Life Sciences.
Axon Therapies has raised $32.0M across 1 funding round. Most recently, it raised $32.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $32.0M Series A | Earlybird Venture Capital, EQT Life Sciences, Seroba Life Sciences |